10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Point of Care Policy for Eliminating Hepatitis C, its Applicability and Acceptability.

      1 , 2 , 3
      Archives of Iranian medicine
      Elimination, National, Rapid, Viral

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chronic infection with hepatitis C virus (HCV), can now be safely treated with oral, well-tolerated medications with >90% success rates, however, currently <5% of the infected individuals have been diagnosed and <1% have received treatment. This is believed to be due to the complicated, time-consuming and expensive disease management processes that require several referrals to specialized laboratories and hospital-based clinics, and also the epidemic of HCV infection among populations who have low uptake for evaluation, appointments, and treatment. Point of care (POC) policy emphasizes on delivering healthcare tests and services to patients at or near the place and time of patient care. A reasonable design for POC policy should contain all parts of the HCV management continuum including screening, diagnosis of viremia, genotyping, cirrhosis evaluation and treatment. Furthermore, successful implementation of this policy requires acceptability from the perspectives of healthcare providers, target populations, and policymakers. In this letter, we discuss the current applicability, acceptability, and cost-effectiveness of POC policy for the management of HCV infection.

          Related collections

          Author and article information

          Journal
          Arch Iran Med
          Archives of Iranian medicine
          1735-3947
          1029-2977
          Sep 01 2018
          : 21
          : 9
          Affiliations
          [1 ] Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
          [2 ] International Agency for Research on Cancer, the World Health Organization (WHO), Lyon, France.
          [3 ] Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran university of Medical Sciences, Tehran, Iran.
          Article
          S1029-2977-21(09)425-0
          30221534
          15e02628-27e2-41f6-ab31-69b8a78c706c

          Elimination,National,Rapid,Viral
          Elimination, National, Rapid, Viral

          Comments

          Comment on this article